5/10/2021

speaker
David
Operator

quarter 2021 conference call. My name is David and I will be the operator for this call. On the call are Paul Wagner, Chairman and Chief Executive Officer of Forte Biosciences, Dan Burge, Forte's Chief Medical Officer, and Tony Riley, Forte's Chief Financial Officer. Before I turn the call over to Paul and Tony to discuss the business and financial highlights of the first quarter, I would like to make a comment regarding forward-looking statements. Many of the statements made during the call today are forward-looking statements. including statements with respect to the company's cash position and the potential development timeline of the company's product candidate. Actual results could differ materially from those contemplated by our forward-looking statements, and reported results should not be considered as an indication of future performance. Please look at our filings with the SEC for a discussion of the factors that could cause our results to differ materially. Additional information is also set forth in Forte's quarterly report on Form 10-Q for the quarter ended March 31, 2021, as filed today with the SEC, and in Forte's annual report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on March 16, 2021. The forward-looking statements on this call are based on information available to us, and we disclaim any obligation to update these forward-looking statements except as required by law. I will now turn this over to Tony, who will discuss the financial highlights of the first quarter of 2021.

speaker
Tony Riley
Chief Financial Officer

Thank you. I will now give an update of our financial results for the first quarter of 2021. We ended the first quarter of 2021 with approximately $54.8 million in cash and cash equivalents, which we believe is sufficient to fund operations for at least the next 12 months as we continue to advance our lead product candidates FB401 through clinical trials. Cash utilization for the first quarter of 2021 was $4.0 million. In terms of operating results, research and development expense were $3.3 million and $1.4 million for the first quarters of 2021 and 2022, respectively. The increases in 2021 were primarily due to manufacturing and clinical development costs and non-cash stock-based compensation expense as we advanced FB401 through phase two clinical trials. We expect our research and development expenses to increase during the next 12 months as we continue the clinical development of FB401. General and administrative expenses were 1.4 and 0.7 million for the first quarters of 2021 and 2020 respectively. The increases in 2021 were primarily due to professional fees for legal auditing and business consulting services and increases in headcount expenses including non-cash stock-based compensation as we scaled operations and became a public company on June 15, 2020. Losses per share were $0.36 and $0.97 for the quarters ended March 31, 2021 and 2020, respectively. Forti had 13.5 million shares of common stock outstanding at the end of the quarter. Additional details And our financial results for the first quarter of 2021 can be found in our Form 10-Q as filed today with the SEC. You can also find more information in the Investor Relations website at www.fortebiorx.com. I will now hand over to Paul.

speaker
Paul Wagner
Chairman and Chief Executive Officer

Great. Thank you, Tony. We're going to keep today's call fairly short, but I wanted to give investors an opportunity to ask any questions that you may have. Before we get to the Q&A, for those of you on the call that are not as familiar with Forte, we're developing FB401, a live biotherapeutic, meaning that this therapy consists of living bacteria, for the treatment of inflammatory skin diseases. And the first focus is on atopic dermatitis. We've been working on FB401 in collaboration with the National Institute of Health and the National Institute of Allergy and Infectious Diseases. Atopic dermatitis is a disease It affects approximately 20 million people in the United States alone, with more than half of those being pediatrics. In fact, one of our thought leaders suggested that number could be as high as 60 to 70% of the population being pediatrics. There's no cure for atopic dermatitis at present, and the treatment options for pediatrics in particular are very limited. We believe there's a significant unmet need for safe and effective therapies to treat these patients, and we're hopeful that FD401 can meet that need. As we've highlighted previously, in October, FDA granted fast track designation to FD401 based on that unmet need and the seriousness of the disease. We completed a Phase IIa study, and that data was published last year in Science Translational Medicine. Just as a quick recap, and I know we've talked about this before, but in that trial, The 20 pediatrics treated for 16 weeks in the 2A trial, FD401 demonstrated a nearly 80% improvement from baseline in atopic dermatitis disease activity as measured by EASY. That's the eczema activity and severity index. And that effect was durable for between three and eight months after stopping therapy. The proportion of patients that had at least a 50% improvement in disease, referred to as EASY 50, was 90%, while the EASY 75 was 70%, and EASY 90 was 30%. In a subgroup of moderate to severe patients, all of them, 100% achieved EZ50, nearly 90% achieved EZ75, and a third achieved the EZ90. As we announced last quarter, we have completed enrollment in the randomized controlled study. We originally targeted enrolling 124 subjects, but due to strong demand, we were able to enroll 154 subjects. The trial enrolled pediatrics, two years of age and older, adolescents and adults, with mild to moderate atopic dermatitis. The majority of those subjects enrolled are under age 18, and the majority are also of moderate disease severity. We expect to announce the results of this trial in the third quarter. In terms of our cash position, as Tony mentioned, at the end of the first quarter of 2021, we had $54.8 million in our cash utilization rate positions as well. We expect to have cash sufficient for at least the next 12 months. Lastly, I'm really pleased to announce that since our last conference call, we had two more patents issued. It brings our total patent portfolio up to 11 in the U.S., and we have similar filings progressing in greater than 15 ex-U.S. countries. So with that, David, we'll now open the call up for Q&A.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-